Corie Lok
Corie Lok is Xconomy's Special Projects Editor. Before joining Xconomy in 2017, she was at Nature for 12 years, first as an editor with the Careers section, then as a senior editor who launched Nature Network (a blogging and social networking website), and finally as an editor and features writer on Nature’s news team.
She earned a master’s degree in science journalism from Boston University and was a producer on the science and health beat for two national radio shows at the Canadian Broadcasting Corporation (CBC) in Toronto. She then spent two years covering emerging technologies with MIT Technology Review before arriving at Nature.
Corie is based in Boston and loves reading stories to her young son and playing the obscure but exciting winter sport of curling.
Recent posts
We’ve received a lot of great nominations for this year’s Xconomy Awards Boston, but we’ve had several people ask for more time to get their nominations in.
So we are... Read more »
As groundbreaking therapies and diagnostics are coming to market, more patients are benefiting from the promise of precision medicine, but many are not, or aren’t able to access the latest treatments... Read more »
The Xconomy Awards categories weren’t enough to capture the full diversity of the San Diego life science community. So we at Xconomy created X of the Year for people who are... Read more »
The Xconomy Awards Boston program has celebrated the best in the area’s life sciences industry for the last two years. We couldn’t have done it without receiving hundreds of nominations of... Read more »
[Corie Lok and Frank Vinluan co-authored this article.] Whether they’re 3D printing human tissues, encoding data in DNA, or securing medical devices against cyber attacks, the finalists in the... Read more »
In an awards program, it can seem like a competition, but in the Commitment to Diversity category, many of the finalists are in fact collaborating with each other or share common... Read more »
If you (or someone you know) is an expert web developer/designer and product manager with a passion for journalism, then we want you!
We’re looking for someone to join our Boston... Read more »
John Maraganore, CEO of Alnylam Pharmaceuticals; Penny Heaton, CEO of the Bill & Melinda Gates Medical Research Institute; digital health leader Pear Therapeutics; and renowned women-in-science advocate and MIT professor emerita... Read more »
Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR editing. Beam’s promise of CRISPR-based therapeutics that... Read more »
After years of boom times, the U.S. biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government... Read more »
Seres Therapeutics was one of the first microbiome companies to form, back in 2010. And the Flagship Pioneering company was the first to go public. But today, faced with the... Read more »
An exciting new area of cell biology research that has emerged in only the last decade has already spawned a startup, which launches today with $60 million in Series A financing.... Read more »
[Updated 12:35pm ET with comments from Michael Gilman, Obsidian CEO, see below.] Bristol-Myers Squibb’s huge proposed buyout of Celgene earlier this month has left many in biotech circles concerned... Read more »
The partial government shutdown could soon become the longest shutdown in history, and biotech firms that have submitted regulatory filings are facing greater uncertainty about their future plans. More than 40... Read more »
Sage Therapeutics could soon win FDA approval for its postpartum depression (PPD) drug brexanalone, a 60-hour infusion supervised by a medical professional that could become the first drug to the... Read more »
Hearing loss drug development continues to attract investment, with Frequency Therapeutics announcing today that it has brought in $42 million in a Series B financing to help it move its treatment... Read more »
A new class of ovarian and breast cancer drugs that thwart a DNA repair mechanism ushered in a novel approach to treating cancer. The first PARP inhibitor was approved in 2014.... Read more »
The race to a peanut allergy treatment just got a little more interesting, with a major player, DBV Technologies withdrawing its application to the FDA for approval of its “Viaskin Peanut”... Read more »
Drugmakers are increasingly turning their attention toward fibrosis, the excessive growth of connective tissue that can lead to scarring and dysfunction of multiple organs including the lungs, liver and kidneys. In... Read more »
[Editor’s note: This is part of a series of posts sharing thoughts from industry and technology leaders about 2018 trends.]
It’s been almost a year since Harvard Pilgrim Health Care signed... Read more »
